[1]
|
Le, M.T., Hamar, P., Guo, C.Y., Basar, E., Perdigão-Henriques, R., Balaj, L. and Lieberman, J. (2014) miR-200- containing extracellular vesicles promote breast cancer cellmetastasis. The Journal of Clinical Investigation, 124, 5109-5128. http://dx.doi.org/10.1172/JCI75695
|
[2]
|
Bovy, N., Blomme, B., Frères, P., Dederen, S., Nivelles, O., Lion, M., Carnet, O., Martial, J.A., Noël, A., Thiry, M., Jérusalem, G., Josse, C., Bours, V., Tabruyn, S.P. and Struman, I. (2015) Endothelial exosomes contribute to the antitumor response during breast cancer neoadjuvant chemotherapy via microRNA transfer. Oncotarget, 6, 10253-10266.
|
[3]
|
Cookson, V.J., Bentley, M.A., Hogan, B.V., Horgan, K., Hayward, B.E., Hazelwood, L.D. and Hughes, T.A. (2012) Circulating microRNA profiles reflect the presence of breast tumours but not the profiles of microRNAs within the tumours. Cellular Oncology, 35, 301-308. http://dx.doi.org/10.1007/s13402-012-0089-1
|
[4]
|
Si, H.Y., Sun, X.M., Chen, Y.J., Cao, Y., Chen, S.M., Wang, H.C. and Hu, C.J. (2013) Circulating microRNA-92a and microRNA-21 as novel minimally invasive biomarkers for primary breast cancer. Journal of Cancer Research and Clinical Oncology, 139, 223-229. http://dx.doi.org/10.1007/s00432-012-1315-y
|
[5]
|
Roth, C., Rack, B., Müller, V., Janni, W., Pantel, K. and Schwarzenbach, H. (2010) Circulating microRNAs as blood- based markers for patients with primary and metastatic breast cancer. Breast Cancer Research, 12, R90.
http://dx.doi.org/10.1186/bcr2766
|
[6]
|
Schwarzenbach, H, Milde-Langosch, K., Steinbach, B., Müller, V. and Pantel, K. (2012) Diagnostic potential of PTEN-targeting miR-214 in the blood of breast cancer patients. Breast Cancer Research and Treatment, 134, 933-941.
http://dx.doi.org/10.1007/s10549-012-1988-6
|
[7]
|
Gao, J., Zhang, Q., Xu, J., Guo, L. and Li, X. (2013) Clinical significance of serum miR-21 in breast cancer compared with CA153 and CEA. Chinese Journal of Cancer Research, 25, 743-748.
|
[8]
|
Liu, L.H., Wang, S., Cao, X.T. and Liu, J.C. (2014) Analysis of circulating microRNA biomarkers for breast cancer detection: A meta-analysis. Tumor Biology, 35, 12245-12253. http://dx.doi.org/10.1007/s13277-014-2533-5
|
[9]
|
Kodahl, A.R., Lyng, M.B., Binder, H., Cold, S., Gravgaard, K., Knoop, A.S. and Ditzel, H.J. (2014) Novel circulating microRNA signature as a potential non-invasive multi-marker test in ER-positive early-stage breast cancer: A case control study. Molecular Oncology, 8, 874-883. http://dx.doi.org/10.1016/j.molonc.2014.03.002
|
[10]
|
Cuk, K., Zucknick, M., Heil, J., Madhavan, D., Schott, S., Turchinovich, A., et al. (2013) Circulating microRNAs in plasma as early detection markers for breast cancer. International Journal of Cancer, 32, 1602-1612.
http://dx.doi.org/10.1002/ijc.27799
|
[11]
|
Madhavan, D., Zucknick, M., Wallwiener, M., Cuk, K., Modugno, C., Scharpff, M., Schott, S., Heil, J., Turchinovich, A., Yang, R.X., Benner, A., Riethdorf, S., Trumpp, A., Sohn, C., Pantel, K., Schneeweiss, A. and Burwinkel, B. (2012) Circulating miRNAs as surrogate markers for circulating tumor cells and prognostic markers in metastatic breast cancer. Clinical Cancer Research, 18, 5972-5982. http://dx.doi.org/10.1158/1078-0432.CCR-12-1407
|
[12]
|
Kleivi Sahlberg, K., Bottai, G., Naume, B., Burwinkel, B., Calin, G.A., Børresen-Dale, A.L. and Santarpia, L. (2015) A serum microRNA signature predicts tumor relapse and survival in triple-negativebreast cancer patients. Clinical Cancer Research, 21, 1207-1214.
|
[13]
|
Eichelser, C., Stückrath, I., Müller, V., Milde-Langosch, K., Wikman, H., Pantel, K. and Schwarzenbach, H. (2014) Increased serum levels of circulating exosomal microRNA-373 in receptor-negative breast cancer patients. Oncotarget, 5, 9650-9663.
|
[14]
|
Jung, E.J., Santarpia, L., Kim, J., Esteva, F.J., Moretti, E., Buzdar, A.U., Di Leo, A., Le, X.F., Bast Jr., R.C., Park, S.T., Pusztai, L. and Calin, G.A. (2012) Plasma microRNA 210 levels correlate with sensitivity to trastuzumab and tumor presence in breast cancer patients. Cancer, 118, 2603-2614. http://dx.doi.org/10.1002/cncr.26565
|
[15]
|
Sun, Y., Wang, M.G., Lin, G.J., Sun, S.P., Li, X.X., Qi, J. and Li, J.M. (2012) Serum microRNA-155 as a potential biomarker to track disease in breast cancer. PLoS ONE, 7, e47003. http://dx.doi.org/10.1371/journal.pone.0047003
|
[16]
|
Anfossi, S., Giordano, A., Gao, H., Cohen, E.N., Tin, S., Wu, Q., et al. (2014) High serum miR-19a levels are associated with inflammatory breast cancer and are predictive of favorable clinical outcome in patients with metastatic HER2+ inflammatory breast cancer. PLoS ONE, 9, e83113. http://dx.doi.org/10.1371/journal.pone.0083113
|
[17]
|
Eroles, P., Tormo, E., Pineda, B., Espin, E. and Lluch, A. (2015) MicroRNAs in breast cancer: one more turn in regulation. Current Drug Targets, (Epub Ahead of Print).
|
[18]
|
Heneghan, H.M., Miller, N., Lowery, A.J., Sweeney, K.J., Newell, J. and Kerin, M.J. (2010) Circulating microRNAs as novel minimally invasive biomarkers for breast cancer. Annals of Surgery, 251, 499-505.
|
[19]
|
Li, Q., Liu, M., Ma, F., Luo, Y., Cai, R.G., Wang, L.M., Xu, N.Z. and Xu, B.H. (2014) Circulating miR-19a and miR-205 in serum may predict the sensitivity of luminal Asubtype of breast cancer patients to neoadjuvant chemotherapy with epirubicin plus paclitaxel. PLoS ONE, 9, e104870.
|
[20]
|
Jung, E.J., Santarpia, L., Kim, J., Esteva, F.J., Moretti, E., Buzdar, A.U., et al. (2012) Plasma microRNA 210 levels correlate with sensitivity to trastuzumab and tumor presence in breast cancer patients. Cancer, 118, 2603-2614.
http://dx.doi.org/10.1002/cncr.26565
|
[21]
|
Müller, V., Gade, S., Steinbach, B., Loibl, S., von Minckwitz, G., Untch, M., Schwedler, K., Lübbe, K., Schem, C., Fasching, P.A., Mau, C., Pantel, K. and Schwarzenbach, H. (2014) Changes in serum levels of miR-21, miR-210, and miR-373 in HER2-positive breast cancer patients undergoing neoadjuvant therapy: A translational research project within the Geparquinto trial. Breast Cancer Research and Treatment, 147, 61-68.
http://dx.doi.org/10.1007/s10549-014-3079-3
|
[22]
|
Ward, A., Shukla, K., Balwierz, A., Soons, Z., König, R., Sahin, O., et al. (2014) MicroRNA-519a is a novel oncomir conferring tamoxifen resistance by targeting a network of tumour-suppressor genes in ER+ breast cancer. The Journal of Pathology, 233, 368-379. http://dx.doi.org/10.1002/path.4363
|
[23]
|
Zhao, H., Shen, J., Medico, L., Wang, D., Ambrosone, C.B. and Liu, S. (2010) A pilot study of circulating miRNAs as potential biomarkers of early stage breast cancer. PLoS ONE, 5, e13735
|
[24]
|
Erbes, T., Hirschfeld, M., Rücker, G., Jaeger, M., Boas, J., Iborra, S., Mayer, S., Gitsch, G. and Stickeler, E. (2015) Feasibility of urinary microRNA detection in breast cancer patients and itspotential as an innovative non-invasive biomarker. BMC Cancer, 15, 193. http://dx.doi.org/10.1186/s12885-015-1190-4
|
[25]
|
Asaga, S. and Hoon, D.S. (2013) Direct serum assay for microRNA in cancer patients. Methods in Molecular Biology, 1024, 147-155. http://dx.doi.org/10.1007/978-1-62703-453-1_11
|